ClinicalTrials.gg
CompletedNCT00489736DIONYSOSUpdated Feb 18, 2010Results posted

Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

A Phase 3 interventional study of dronedarone (SR33589) and amiodarone in Atrial Fibrillation, sponsored by Sanofi. Completed at 23 sites in 23 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2010-02-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
6th of 26
504 · median 164
Started
2007
the only one that year
Phase 3
7 of 26
none open now
Registered
4th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 3, and was the 4th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • sinus rhythm
  • amiodarone
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with documented atrial fibrillation for more than 72 hours for whom cardioversion and antiarrhythmic treatment is indicated in the opinion of the investigator and under oral anticoagulation

Exclusion criteria

Exclusion Criteria:

  • to oral anticoagulation
  • Patient having received amiodarone in the past whatever the date (more than a total of twenty 200 mg tablets or more than 5 days intravenous)
  • Patients known to have chronic AF, patients with atrial flutter or paroxysmal atrial fibrillation
  • Severe congestive heart failure with New-York Heart Association () class III or IV, severe bradycardia, high degree atrio-ventricular block, ongoing potentially dangerous symptoms when in AF such as angina pectoris, , stroke, syncope, as judged by the investigator, first degree family history of sudden cardiac death below age 50 years in the absence of coronary heart disease, significant sinus node disease without a permanent pacemaker implanted
  • History of torsades de pointes or long syndrome or QT- or QTc-interval ≥500 msecs before randomization
  • Treatment with other class I or III antiarrhythmic drugs which cannot be discontinued
  • Dysthyroidism or other contraindication to amiodarone

The above information are not intended to contain all the considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    Dronedarone 400mg bid

    dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg

    Drug: dronedarone (SR33589)

  • Active comparator
    Amiodarone 600mg/200mg od

    over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets

    Drug: amiodarone

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Failure

    The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum study duration is 6 months (+10 days); maximum is 15 months

Secondary outcomes

  1. Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event

    The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum study duration is 6 months (+10 days); maximum is 15 months

Other outcomes

  1. Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting

    The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.

    Time frame: minimum study duration is 6 months (+10 days); maximum is 15 months

07

Results

Posted Nov 9, 2009

Participant flow

Enrollment of patients started on June 12, 2007 and was completed on October 3, 2008. The study was conducted in 112 centers in 23 countries. Minimum duration of treatment was 6 months. Minimum duration of observation was last patient's randomization plus 190 days.

Participant flow — Overall Study
MilestoneDronedarone 400mg BidAmiodarone 600mg/200mg od
Started249255
Completed153186
Not completed9669
Withdrew: Lack of efficacy5314
Withdrew: Adverse event3245
Withdrew: Poor compliance62
Withdrew: Not coded/ not pre-specified58

Outcome measures

PrimaryTreatment Failure

The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum study duration is 6 months (+10 days); maximum is 15 months
Reported as:
Number · participants
Treatment Failure
participantsDronedarone 400mg BidAmiodarone 600mg/200mg od
Treatment Failure184 (37.0 to 45.0)141 (99.0 to 275.0)
Statistical analysis
  • Dronedarone 400mg Bid vs Amiodarone 600mg/200mg od · Log Rank · p = <0.0001 (Cumulative incidence functions in each treatment group were calculated using time-to-event non-parametric Kaplan-Meier estimate. The primary comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 1.59 · 95% CI 1.28 to 1.98The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It provides the relative hazard of treatment failure for the dronedarone group compared with the amiodarone group.
SecondaryOccurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event

The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum study duration is 6 months (+10 days); maximum is 15 months
Reported as:
Number · participants
Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event
participantsDronedarone 400mg BidAmiodarone 600mg/200mg od
Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event83107
Statistical analysis
  • Dronedarone 400mg Bid vs Amiodarone 600mg/200mg od · Log Rank · p = 0.13 (Cumulative incidence functions in each treatment group were calculated using time-to-event non-parametric Kaplan-Meier estimate. The comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 0.80 · 95% CI 0.60 to 1.07The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It provides the relative hazard of main safety event occurrence for the dronedarone group compared with the amiodarone group.
Other pre-specifiedOccurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting

The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.

Time frame:
minimum study duration is 6 months (+10 days); maximum is 15 months
Reported as:
Number · participants
Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting
participantsDronedarone 400mg BidAmiodarone 600mg/200mg od
Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting6199
Statistical analysis
  • Dronedarone 400mg Bid vs Amiodarone 600mg/200mg od · Log Rank · p = 0.002 (Cumulative incidence functions in each treatment group were calculated using time-to-event non-parametric Kaplan-Meier estimate. The comparison was performed at the 5% level using a 2-sided Log rank test.) · Hazard ratio (hr): 0.61 · 95% CI 0.44 to 0.84The hazard ratio was estimated by a Cox's proportional hazard model with treatment arm factor. It provides the relative hazard of MSE occurrence excluding gastrointestinal events, for the dronedarone group compared with the amiodarone group.

Adverse events

Collected over From first to last study drug intake +10 days i.e. end of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dronedarone 400mg Bid—34/249 (13.7%)146/249 (58.6%)
Amiodarone 600mg/200mg od—37/255 (14.5%)165/255 (64.7%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventDronedarone 400mg BidAmiodarone 600mg/200mg od
Cardiac failureCardiac disorders6/2491/255
Cardiac failure congestiveCardiac disorders1/2496/255
Therapeutic agent toxicityInjury, poisoning and procedural complications1/2493/255
PneumoniaInfections and infestations2/2490/255
BradycardiaCardiac disorders1/2492/255
BronchitisInfections and infestations0/2492/255
SyncopeNervous system disorders0/2492/255
Accidental overdoseInjury, poisoning and procedural complications0/2492/255
International normalised ratio increasedInvestigations0/2492/255
Angina pectorisCardiac disorders1/2491/255
Most frequent other events
Showing 10 of 22
Most frequent other events
EventDronedarone 400mg BidAmiodarone 600mg/200mg od
Any Gastrointestinal disordersGastrointestinal disorders54/24944/255
Any Nervous system disordersNervous system disorders17/24939/255
Any Cardiac disordersCardiac disorders21/24936/255
Any Infections and infestationsInfections and infestations35/24935/255
Any InvestigationsInvestigations33/24935/255
Any General disorders and administration site conditionsGeneral disorders14/24926/255
DiarrhoeaGastrointestinal disorders23/2498/255
Any Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders18/24923/255
Any Vascular disordersVascular disorders9/24923/255
Any Psychiatric disordersPsychiatric disorders6/24923/255

Baseline characteristics

Age, Customized
Age, Customized(participants)Dronedarone 400mg BidAmiodarone 600mg/200mg odTotal
18 to < 65 years125138263
65 to < 75 years7670146
>= 75 years484795
Age Continuous
Age Continuous(years)Dronedarone 400mg BidAmiodarone 600mg/200mg odTotal
Mean64.4 ± 10.863.7 ± 10.664.0 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Dronedarone 400mg BidAmiodarone 600mg/200mg odTotal
Female7373146
Male176182358
08

Study locations

23 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-Aventis Administrative Office
    Cove, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Santiago, Chile
  • Sanofi-Aventis Administrative Office
    Shangaï, China
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Tallinn, Estonia
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Casablanca, Morocco
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Megrine, Tunisia
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
09

References and documents

Publications

  • Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. doi: 10.1111/j.1540-8167.2010.01764.x. Epub 2010 Apr 6. PubMed 20384650 ↗
  • Ezekowitz MD. Maintaining sinus rhythm--making treatment better than the disease. N Engl J Med. 2007 Sep 6;357(10):1039-41. doi: 10.1056/NEJMe078148. No abstract available. PubMed 17804851 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2007
First posted
Jun 21, 2007
Start
Jun 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 9, 2009
Last update
Feb 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00489736
Lead sponsor
Sanofi
First posted
Jun 21, 2007
Start date
Jun 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 9, 2009
Last update
Feb 18, 2010

Study contacts

International Clinical Development
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion